Healthcare
Based on ARK ETF real-time + 13F quarterly filings
13F data may be delayed up to 90 days.
※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.
Beam Therapeutics is a biotechnology company developing precision genetic medicines for serious diseases. Their main products include novel base editing therapies for sickle cell disease, alpha-1 antitrypsin deficiency, and glycogen storage disease 1a, with a pipeline targeting various genetic disorders. Beam is positioned as an innovator in the field of genetic medicine, with strategic collaborations with major pharmaceutical companies.
AI-generated summary. Not investment advice.